Prospects of minimally invasive surgery in the treatment of primary open-angle glaucoma

Abstract

The article examines the prospects of minimally invasive glaucoma surgery in the treatment of primary open-angle glaucoma. The primary focus is on the effectiveness and safety of contemporary minimally invasive glaucoma surgery techniques, such as iStent, MicroShunt, and Hydrus. The authors highlight the significant reduction in intraocular pressure and the decrease in dependence on medication therapy for most patients following these procedures. The article presents results from numerous clinical studies demonstrating the high effectiveness and safety of these methods. The uniqueness of this review lies in the comprehensive analysis of current data and the identification of key advantages of minimally invasive glaucoma surgery compared to traditional glaucoma treatment methods. The article also emphasizes the economic feasibility of minimally invasive glaucoma surgery, which can significantly reduce the burden on healthcare systems in various regions. The authors point out the necessity for further research to evaluate the long-term effectiveness and safety of these technologies, as well as to determine optimal management strategies for primary open-angle glaucoma in different population subgroups. Detailed meta-analyses and multicenter studies could contribute to better understanding of the mechanisms of action and potential limitations of these technologies, providing a basis for personalized approach to glaucoma treatment.

Keywords

open-angle glaucoma / intraocular pressure / minimally invasive surgical procedures / glaucoma / implants

References

[1] Primary open-angle glaucoma. Clinical recommendations. Ministry of Health of the Russian Federation. 2020. 62 p.

[2] Глаукома первичная открытоугольная. Клинические рекомендации. Министерство здравоохранения Российской Федерации. 2020. 62 c.

[3] Primary open-angle glaucoma. Clinical recommendations. Ministry of Health of the Russian Federation. 2020. 62 p.

[4] Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(12): e1221–e1234. doi: 10.1016/S2214–109X(17)30393–5

[5] Flaxman S.R., Bourne R.R.A., Resnikoff S., et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis // The Lancet Global Health. 2017. Vol. 5, N 12. P. e1221–e1234. doi: 10.1016/S2214-109X(17)30393-5

[6] Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(12): e1221–e1234. doi: 10.1016/S2214–109X(17)30393–5

[7] Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020;12(11): e11686. doi: 10.7759/cureus.11686

[8] Allison K., Patel D., Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future // Cureus. 2020. Vol. 12, N 11. P. e11686. doi: 10.7759/cureus.11686

[9] Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020;12(11): e11686. doi: 10.7759/cureus.11686

[10] Movsisyan AB, Kuroedov AV, Arkharov MA, et al. Epidemiological analysis primary open-angle glaucoma incidence and prevalence in Russia. Russian Journal of Clinical Ophthalmology. 2022;22(1):3–10. EDN: VIMPIU doi: 10.32364/2311–7729–2022–22–1–3–10

[11] Мовсисян А.Б., Куроедов А.В., Архаров М.А., и др. Эпидемиологический анализ заболеваемости и распространенности первичной открытоугольной глаукомы в Российской Федерации // РМЖ. Клиническая офтальмология. 2022. Т. 22, № 1. С. 3–10. EDN: VIMPIU doi: 10.32364/2311-7729-2022-22-1-3-10

[12] Movsisyan AB, Kuroedov AV, Arkharov MA, et al. Epidemiological analysis primary open-angle glaucoma incidence and prevalence in Russia. Russian Journal of Clinical Ophthalmology. 2022;22(1):3–10. EDN: VIMPIU doi: 10.32364/2311–7729–2022–22–1–3–10

[13] Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review // JAMA. 2014;311(18):1901–1911. doi: 10.1001/jama.2014.3192

[14] Weinreb R.N., Aung T., Medeiros F.A. The pathophysiology and treatment of glaucoma: a review // JAMA. 2014. Vol. 311, N 18. P. 1901–1911. doi: 10.1001/jama.2014.3192

[15] Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review // JAMA. 2014;311(18):1901–1911. doi: 10.1001/jama.2014.3192

[16] Balas M, Mathew DJ. Minimally invasive glaucoma surgery: a review of the literature. Vision. 2023;7(3):54. doi: 10.3390/vision7030054

[17] Balas M., Mathew D.J. Minimally invasive glaucoma surgery: a review of the literature // Vision. 2023. Vol. 7, N 3. P. 54. doi: 10.3390/vision7030054

[18] Balas M, Mathew DJ. Minimally invasive glaucoma surgery: a review of the literature. Vision. 2023;7(3):54. doi: 10.3390/vision7030054

[19] Gambini G, Carlà MM, Giannuzzi F, et al. PreserFlo® MicroShunt: an overview of this minimally invasive device for open-angle glaucoma. Vision. 2022;6(1):12. doi: 10.3390/vision6010012

[20] Gambini G., Carlà M.M., Giannuzzi F., et al. PreserFlo® MicroShunt: an overview of this minimally invasive device for open-angle glaucoma // Vision. 2022. Vol. 6, N 1. P. 12. doi: 10.3390/vision6010012

[21] Gambini G, Carlà MM, Giannuzzi F, et al. PreserFlo® MicroShunt: an overview of this minimally invasive device for open-angle glaucoma. Vision. 2022;6(1):12. doi: 10.3390/vision6010012

[22] Pinchuk L, Riss I, Batlle JF, et al. The development of a micro-shunt made from poly (styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017;105(1):211–221. doi: 10.1002/jbm.b.33558

[23] Pinchuk L., Riss I., Batlle J.F., et al. The development of a micro-shunt made from poly (styrene-block-isobutylene-block-styrene) to treat glaucoma // J Biomed Mater Res B Appl Biomater. 2017. Vol. 105, N 1. P. 211–221. doi: 10.1002/jbm.b.33558

[24] Pinchuk L, Riss I, Batlle JF, et al. The development of a micro-shunt made from poly (styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017;105(1):211–221. doi: 10.1002/jbm.b.33558

[25] Saeed E, Gołaszewska K, Dmuchowska DA, et al. The PreserFlo microshunt in the context of minimally invasive glaucoma surgery: a narrative review. Int J Environ Res Public Health. 2023;20(4):2904. doi: 10.3390/ijerph20042904

[26] Saeed E., Gołaszewska K., Dmuchowska D.A., et al. The PreserFlo microshunt in the context of minimally invasive glaucoma surgery: a narrative review // Int J Environ Res Public Health. 2023. Vol. 20, N 4. P. 2904. doi: 10.3390/ijerph20042904

[27] Saeed E, Gołaszewska K, Dmuchowska DA, et al. The PreserFlo microshunt in the context of minimally invasive glaucoma surgery: a narrative review. Int J Environ Res Public Health. 2023;20(4):2904. doi: 10.3390/ijerph20042904

[28] Sadruddin O, Pinchuk L, Angeles R, Palmberg P. Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: A review. Eye Vis. 2019;6:36. doi: 10.1186/s40662-019-0162-1

[29] Sadruddin O., Pinchuk L., Angeles R., Palmberg P. Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: A review // Eye Vis. 2019. Vol. 6. P. 36. doi: 10.1186/s40662-019-0162-1

[30] Sadruddin O, Pinchuk L, Angeles R, Palmberg P. Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: A review. Eye Vis. 2019;6:36. doi: 10.1186/s40662-019-0162-1

[31] Baker ND, Barnebey HS, Moster MR, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128(12):1710–1721. doi: 10.1016/j.ophtha.2021.05.023

[32] Baker N.D., Barnebey H.S., Moster M.R., et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study // Ophthalmology. 2021. Vol. 128, N 12. P. 1710–1721. doi: 10.1016/j.ophtha.2021.05.023

[33] Baker ND, Barnebey HS, Moster MR, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128(12):1710–1721. doi: 10.1016/j.ophtha.2021.05.023

[34] Panarelli JF, Moster MR, Garcia-Feijoo J, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: two-year results from a randomized, multicenter study. Ophthalmology. 2024;131(3):266–276. doi: 10.1016/j.ophtha.2023.09.023

[35] Panarelli J.F., Moster M.R., Garcia-Feijoo J., et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: two-year results from a randomized, multicenter study // Ophthalmology. 2024. Vol. 131, N 3. P. 266–276. doi: 10.1016/j.ophtha.2023.09.023

[36] Panarelli JF, Moster MR, Garcia-Feijoo J, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: two-year results from a randomized, multicenter study. Ophthalmology. 2024;131(3):266–276. doi: 10.1016/j.ophtha.2023.09.023

[37] Mansouri K, Shaarawy T. Update on Schlemm’s canal based procedures. Middle East African Journal of Ophthalmology. 2015;22(1):38–44. doi: 10.4103/0974–9233.148347

[38] Mansouri K., Shaarawy T. Update on Schlemm’s canal based procedures // Middle East African Journal of Ophthalmology. 2015. Vol. 22, N 1. P. 38–44. doi: 10.4103/0974-9233.148347

[39] Mansouri K, Shaarawy T. Update on Schlemm’s canal based procedures. Middle East African Journal of Ophthalmology. 2015;22(1):38–44. doi: 10.4103/0974–9233.148347

[40] Ahmed IIK, Rhee DJ, Jones J, et al. Three-year findings of the HORIZON Trial: a Schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology. 2021;128(6):857–865. doi: 10.1016/j.ophtha.2020.11.004

[41] Ahmed I.I.K., Rhee D.J., Jones J., et al. Three-year findings of the HORIZON Trial: a Schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract // Ophthalmology. 2021. Vol. 128, N 6. P. 857–865. doi: 10.1016/j.ophtha.2020.11.004

[42] Ahmed IIK, Rhee DJ, Jones J, et al. Three-year findings of the HORIZON Trial: a Schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology. 2021;128(6):857–865. doi: 10.1016/j.ophtha.2020.11.004

[43] Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology. 2019;126(1):29–37. doi: 10.1016/j.ophtha.2018.05.012

[44] Samuelson T.W., Chang D.F., Marquis R., et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study // Ophthalmology. 2019. Vol. 126, N 1. P. 29–37. doi: 10.1016/j.ophtha.2018.05.012

[45] Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology. 2019;126(1):29–37. doi: 10.1016/j.ophtha.2018.05.012

[46] De Francesco T, Ahmed IIK. Surgical augmentation of the suprachoroidal space: a novel material and implant. Clin Ophthalmol. 2023:2483–2492. doi: 10.2147/OPTH.S409958

[47] De Francesco T., Ahmed I.I.K. Surgical augmentation of the suprachoroidal space: a novel material and implant // Clin Ophthalmol. 2023. P. 2483–2492. doi: 10.2147/OPTH.S409958

[48] De Francesco T, Ahmed IIK. Surgical augmentation of the suprachoroidal space: a novel material and implant. Clin Ophthalmol. 2023:2483–2492. doi: 10.2147/OPTH.S409958

[49] Grierson I, Minckler D, Rippy MK, et al. A novel suprachoroidal microinvasive glaucoma implant: in vivo biocompatibility and biointegration. BMC Biomed Eng. 2020;2:1–10. doi: 10.1186/s42490-020-00045-1

[50] Grierson I., Minckler D., Rippy M.K., et al. A novel suprachoroidal microinvasive glaucoma implant: in vivo biocompatibility and biointegration // BMC Biomed Eng. 2020. Vol. 2. P. 1–10. doi: 10.1186/s42490-020-00045-1

[51] Grierson I, Minckler D, Rippy MK, et al. A novel suprachoroidal microinvasive glaucoma implant: in vivo biocompatibility and biointegration. BMC Biomed Eng. 2020;2:1–10. doi: 10.1186/s42490-020-00045-1

[52] Denis P, Hirneiß C, Reddy KP, et al. A first-in-human study of the efficacy and safety of MINIject in patients with medically uncontrolled open-angle glaucoma (STAR-I). Ophthalmol Glaucoma. 2019;2(5):290–297. doi: 10.1016/j.ogla.2019.06.001

[53] Denis P., Hirneiß C., Reddy K.P., et al. A first-in-human study of the efficacy and safety of MINIject in patients with medically uncontrolled open-angle glaucoma (STAR-I) // Ophthalmol Glaucoma. 2019. Vol. 2, N 5. P. 290–297. doi: 10.1016/j.ogla.2019.06.001

[54] Denis P, Hirneiß C, Reddy KP, et al. A first-in-human study of the efficacy and safety of MINIject in patients with medically uncontrolled open-angle glaucoma (STAR-I). Ophthalmol Glaucoma. 2019;2(5):290–297. doi: 10.1016/j.ogla.2019.06.001

[55] Denis P, Hirneiß C, Durr GM, et al. Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial. Br J Ophthalmol. 2022;106(1):65–70. doi: 10.1136/bjophthalmol-2020-316888

[56] Denis P., Hirneiß C., Durr G.M., et al. Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial // Br J Ophthalmol. 2022. Vol. 106, N 1. P. 65–70. doi: 10.1136/bjophthalmol-2020-316888

[57] Denis P, Hirneiß C, Durr GM, et al. Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial. Br J Ophthalmol. 2022;106(1):65–70. doi: 10.1136/bjophthalmol-2020-316888

[58] Shalaby WS, Lam SS, Arbabi A, et al. iStent versus iStent inject implantation combined with phacoemulsification in open angle glaucoma. Indian J Ophthalmol. 2021;69(9):2488–2495. doi: 10.4103/ijo.IJO_308_21

[59] Shalaby W.S., Lam S.S., Arbabi A., et al. iStent versus iStent inject implantation combined with phacoemulsification in open angle glaucoma // Indian J Ophthalmol. 2021. Vol. 69, N 9. P. 2488–2495. doi: 10.4103/ijo.IJO_308_21

[60] Shalaby WS, Lam SS, Arbabi A, et al. iStent versus iStent inject implantation combined with phacoemulsification in open angle glaucoma. Indian J Ophthalmol. 2021;69(9):2488–2495. doi: 10.4103/ijo.IJO_308_21

[61] Samuelson TW, Sarkisian SRJr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811–821. doi: 10.1016/j.ophtha.2019.03.006

[62] Samuelson T.W., Sarkisian S.R. Jr., Lubeck D.M., et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results // Ophthalmology. 2019. Vol. 126, N 6. P. 811–821. doi: 10.1016/j.ophtha.2019.03.006

[63] Samuelson TW, Sarkisian SRJr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811–821. doi: 10.1016/j.ophtha.2019.03.006

[64] Ahmed IIK, Podbielski DW, Patel V, et al. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma. Ophthalmol Glaucoma. 2020;3(2):103–113. doi: 10.1016/j.ogla.2019.11.009

[65] Ahmed I.I.K., Podbielski D.W., Patel V., et al. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma // Ophthalmol Glaucoma. 2020. Vol. 3, N 2. P. 103–113. doi: 10.1016/j.ogla.2019.11.009

[66] Ahmed IIK, Podbielski DW, Patel V, et al. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma. Ophthalmol Glaucoma. 2020;3(2):103–113. doi: 10.1016/j.ogla.2019.11.009

[67] Fea AM, Cattel F, Gandolfi S, et al. Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle glaucoma in Italy. BMC Health Serv Res. 2021;21:1–12. doi: 10.1186/s12913-021-06862-x

[68] Fea A.M., Cattel F., Gandolfi S., et al. Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle glaucoma in Italy // BMC Health Serv Res. 2021. Vol. 21. P. 1–12. doi: 10.1186/s12913-021-06862-x

[69] Fea AM, Cattel F, Gandolfi S, et al. Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle glaucoma in Italy. BMC Health Serv Res. 2021;21:1–12. doi: 10.1186/s12913-021-06862-x

[70] Lima FE, Geraissate JC, Ávila M.P. A multicenter prospective comparative study evaluating cataract surgery and endoscopic cyclophotocoagulation either with or without iStent Inject implantation in Brazilian patients with glaucoma. Int Ophthalmol. 2023;43(5): 1665–1676. doi: 10.1007/s10792-022-02563-4

[71] Lima F.E., Geraissate J.C., Ávila M.P. A multicenter prospective comparative study evaluating cataract surgery and endoscopic cyclophotocoagulation either with or without iStent Inject implantation in Brazilian patients with glaucoma // Int Ophthalmol. 2023. Vol. 43, N 5. P. 1665–1676. doi: 10.1007/s10792-022-02563-4

[72] Lima FE, Geraissate JC, Ávila M.P. A multicenter prospective comparative study evaluating cataract surgery and endoscopic cyclophotocoagulation either with or without iStent Inject implantation in Brazilian patients with glaucoma. Int Ophthalmol. 2023;43(5): 1665–1676. doi: 10.1007/s10792-022-02563-4

[73] Guo CY, Qi XH, Qi JM. Systematic review and meta-analysis of treating open angle glaucoma with gonioscopy-assisted transluminal trabeculotomy. Int J Ophthalmol. 2020;13(2):317. doi: 10.18240/ijo.2020.02.17

[74] Guo C.Y., Qi X.H., Qi J.M. Systematic review and meta-analysis of treating open angle glaucoma with gonioscopy-assisted transluminal trabeculotomy // Int J Ophthalmol. 2020. Vol. 13, N 2. P. 317. doi: 10.18240/ijo.2020.02.17

[75] Guo CY, Qi XH, Qi JM. Systematic review and meta-analysis of treating open angle glaucoma with gonioscopy-assisted transluminal trabeculotomy. Int J Ophthalmol. 2020;13(2):317. doi: 10.18240/ijo.2020.02.17

[76] Faria BM, Costa VP, Melillo GH, et al. Gonioscopy-assisted transluminal trabeculotomy for glaucoma: 1-year outcomes and success predictors. J Glaucoma. 2022;31(6):443–448. doi: 10.1097/IJG.0000000000002025

[77] Faria B.M., Costa V.P., Melillo G.H., et al. Gonioscopy-assisted transluminal trabeculotomy for glaucoma: 1-year outcomes and success predictors // J Glaucoma. 2022. Vol. 31, N 6. P. 443–448. doi: 10.1097/IJG.0000000000002025

[78] Faria BM, Costa VP, Melillo GH, et al. Gonioscopy-assisted transluminal trabeculotomy for glaucoma: 1-year outcomes and success predictors. J Glaucoma. 2022;31(6):443–448. doi: 10.1097/IJG.0000000000002025

[79] Bozkurt E, Yenihayat F, Olgun A, et al. The efficacy of gonioscopy-assisted transluminal trabeculectomy combined with phacoemulsification. Int Ophthalmol. 2021;41:35–43. doi: 10.1007/s10792-020-01550-x

[80] Bozkurt E., Yenihayat F., Olgun A., et al. The efficacy of gonioscopy-assisted transluminal trabeculectomy combined with phacoemulsification // Int Ophthalmol. 2021. Vol. 41. P. 35–43. doi: 10.1007/s10792-020-01550-x

[81] Bozkurt E, Yenihayat F, Olgun A, et al. The efficacy of gonioscopy-assisted transluminal trabeculectomy combined with phacoemulsification. Int Ophthalmol. 2021;41:35–43. doi: 10.1007/s10792-020-01550-x

[82] Fontana L, De Maria M, Iannetta D, Moramarco A. Gonioscopy-assisted transluminal trabeculotomy for chronic angle-closure glaucoma: preliminary results. Graefes Arch Clin Exp Ophthalmol. 2021;260(2):3019–3026. doi: 10.1007/s00417-020-05400-z

[83] Fontana L., De Maria M., Iannetta D., Moramarco A. Gonioscopy-assisted transluminal trabeculotomy for chronic angle-closure glaucoma: preliminary results // Graefes Arch Clin Exp Ophthalmol. 2021. Vol. 260, N 2. P. 3019–3026. doi: 10.1007/s00417-020-05400-z

[84] Fontana L, De Maria M, Iannetta D, Moramarco A. Gonioscopy-assisted transluminal trabeculotomy for chronic angle-closure glaucoma: preliminary results. Graefes Arch Clin Exp Ophthalmol. 2021;260(2):3019–3026. doi: 10.1007/s00417-020-05400-z

[85] Sharkawi E, Artes PH, Lindegger DJ, et al. Gonioscopy-assisted transluminal trabeculotomy in primary angle-closure glaucoma. Graefes Arch Clin Exp Ophthalmol. 2021;259(10):3019–3026. doi: 10.1007/s00417–021–05244–7

[86] Sharkawi E., Artes P.H., Lindegger D.J., et al. Gonioscopy-assisted transluminal trabeculotomy in primary angle-closure glaucoma // Graefes Arch Clin Exp Ophthalmol. 2021. Vol. 259, N 10. P. 3019–3026. doi: 10.1007/s00417-021-05244-7

[87] Sharkawi E, Artes PH, Lindegger DJ, et al. Gonioscopy-assisted transluminal trabeculotomy in primary angle-closure glaucoma. Graefes Arch Clin Exp Ophthalmol. 2021;259(10):3019–3026. doi: 10.1007/s00417–021–05244–7

[88] Olgun A, Aktas Z, Ucgul AY. XEN gel implant versus gonioscopy-assisted transluminal trabeculotomy for the treatment of open-angle glaucoma. Int Ophthalmol. 2020;40(5):1085–1093. doi: 10.1007/s10792-019-01271-w

[89] Olgun A., Aktas Z., Ucgul A.Y. XEN gel implant versus gonioscopy-assisted transluminal trabeculotomy for the treatment of open-angle glaucoma // Int Ophthalmol. 2020. Vol. 40, N 5. P. 1085–1093. doi: 10.1007/s10792-019-01271-w

[90] Olgun A, Aktas Z, Ucgul AY. XEN gel implant versus gonioscopy-assisted transluminal trabeculotomy for the treatment of open-angle glaucoma. Int Ophthalmol. 2020;40(5):1085–1093. doi: 10.1007/s10792-019-01271-w

[91] Hamze H, Mohite AA, Pandey P, et al. Comparison of 1-year surgical outcomes of combined cataract surgery and gonioscopy-assisted transluminal trabeculotomy (GATT) versus cataract surgery and iStent Inject. Graefes Arch Clin Exp Ophthalmol. 2021;259(10): 3035–3044. doi: 10.1007/s00417-021-05133-z

[92] Hamze H., Mohite A.A., Pandey P., et al. Comparison of 1-year surgical outcomes of combined cataract surgery and gonioscopy-assisted transluminal trabeculotomy (GATT) versus cataract surgery and iStent Inject // Graefes Arch Clin Exp Ophthalmol. 2021. Vol. 259, N 10. P. 3035–3044. doi: 10.1007/s00417-021-05133-z

[93] Hamze H, Mohite AA, Pandey P, et al. Comparison of 1-year surgical outcomes of combined cataract surgery and gonioscopy-assisted transluminal trabeculotomy (GATT) versus cataract surgery and iStent Inject. Graefes Arch Clin Exp Ophthalmol. 2021;259(10): 3035–3044. doi: 10.1007/s00417-021-05133-z

[94] Wang Y, Zhang W, Xin C, et al. Gonioscopy-assisted transluminal trabeculotomy for open-angle glaucoma with failed incisional glaucoma surgery: two-year results. BMC Ophthalmol. 2023;23(1):89. doi: 10.1186/s12886-023-02830-7

[95] Wang Y., Zhang W., Xin C., et al. Gonioscopy-assisted transluminal trabeculotomy for open-angle glaucoma with failed incisional glaucoma surgery: two-year results // BMC Ophthalmol. 2023. Vol. 23, N 1. P. 89. doi: 10.1186/s12886-023-02830-7

[96] Wang Y, Zhang W, Xin C, et al. Gonioscopy-assisted transluminal trabeculotomy for open-angle glaucoma with failed incisional glaucoma surgery: two-year results. BMC Ophthalmol. 2023;23(1):89. doi: 10.1186/s12886-023-02830-7

[97] Fea AM, Durr GM, Marolo P, et al. XEN® gel stent: a comprehensive review on its use as a treatment option for refractory glaucoma. Clin Ophthalmol. 2020;14:1805–1832. doi: 10.2147/OPTH.S178348

[98] Fea A.M., Durr G.M., Marolo P., et al. XEN® gel stent: a comprehensive review on its use as a treatment option for refractory glaucoma // Clin Ophthalmol. 2020. Vol. 14. P. 1805–1832. doi: 10.2147/OPTH.S178348

[99] Fea AM, Durr GM, Marolo P, et al. XEN® gel stent: a comprehensive review on its use as a treatment option for refractory glaucoma. Clin Ophthalmol. 2020;14:1805–1832. doi: 10.2147/OPTH.S178348

[100] Sheybani A, Vera V, Grover DS, et al. Gel stent versus trabeculectomy: the randomized, multicenter, gold-standard pathway study (GPS) of effectiveness and safety at 12 months. Am J Ophthalmol. 2023;252:306–325. doi: 10.1016/j.ajo.2023.03.026

[101] Sheybani A., Vera V., Grover D.S., et al. Gel stent versus trabeculectomy: the randomized, multicenter, gold-standard pathway study (GPS) of effectiveness and safety at 12 months // Am J Ophthalmol. 2023. Vol. 252. P. 306–325. doi: 10.1016/j.ajo.2023.03.026

[102] Sheybani A, Vera V, Grover DS, et al. Gel stent versus trabeculectomy: the randomized, multicenter, gold-standard pathway study (GPS) of effectiveness and safety at 12 months. Am J Ophthalmol. 2023;252:306–325. doi: 10.1016/j.ajo.2023.03.026

[103] Fea AM, Bron AM, Economou MA, et al. European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma. J Cataract Refract Surg. 2020;46(3):441–450. doi: 10.1097/j.jcrs.0000000000000065

[104] Fea A.M., Bron A.M., Economou M.A., et al. European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma // J Cataract Refract Surg. 2020. Vol. 46, N 3. P. 441–450. doi: 10.1097/j.jcrs.0000000000000065

[105] Fea AM, Bron AM, Economou MA, et al. European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma. J Cataract Refract Surg. 2020;46(3):441–450. doi: 10.1097/j.jcrs.0000000000000065

[106] Chan L, Moster MR, Bicket AK, et al. New devices in glaucoma. Ophthalmol Ther. 2023;12(5):2381–2395. doi: 10.1007/s40123-023-00780-3

[107] Chan L., Moster M.R., Bicket A.K., et al. New devices in glaucoma // Ophthalmol Ther. 2023. Vol. 12, N 5. P. 2381–2395. doi: 10.1007/s40123-023-00780-3

[108] Chan L, Moster MR, Bicket AK, et al. New devices in glaucoma. Ophthalmol Ther. 2023;12(5):2381–2395. doi: 10.1007/s40123-023-00780-3

[109] Geffen N, Kumar DA, Barayev E, et al. minimally invasive micro sclerostomy (MIMS) procedure: a novel glaucoma filtration procedure. J Glaucoma. 2022;31(3):191–200. doi: 10.1097/IJG.0000000000001955

[110] Geffen N., Kumar D.A., Barayev E., et al. minimally invasive micro sclerostomy (MIMS) procedure: a novel glaucoma filtration procedure // J Glaucoma. 2022. Vol. 31, N 3. P. 191–200. doi: 10.1097/IJG.0000000000001955

[111] Geffen N, Kumar DA, Barayev E, et al. minimally invasive micro sclerostomy (MIMS) procedure: a novel glaucoma filtration procedure. J Glaucoma. 2022;31(3):191–200. doi: 10.1097/IJG.0000000000001955

RIGHTS & PERMISSIONS

Eco-Vector